WESTON, Fla., Nov. 4, 2016 /PRNewswire/ -- Apotex Corp. announced today the extension of the Imatinib Instant Savings* Card Program. The Instant Savings* Card Program extension was made to ensure that Apotex is assisting as many qualified patients to have access to Imatinib. Photo - http://photos.prnewswire.com/prnh/20161104/436230 The extension ensures Imatinib Instant Savings* Card Program benefits are available to qualified new patients as well as currently enrolled patients through December 31, 2016. The Imatinib Instant Savings* Card Program website ( www.ImatinibZeroCopay.com) is designed to provide patients and prescribers detailed information about the benefits of enrolling in the Imatinib Instant Savings* Card Program as well as Imatinib Mesylate Tablet product information. Patients can learn more about the Imatinib Instant Savings* Card Program by visiting the website or calling toll free 877-336-2187. Apotex launched Imatinib Mesylate Tablets, the generic equivalent of Gleevec® by Novartis in 100mg and 400mg strengths earlier this year. According to IMS Health, Gleevec® had approximately $2.4 billion in sales in the 12 months ending in May 2016. Extending Apotex's Imatinib Instant Savings* Card Program is just another example of how Apotex is everywhere. Making a difference. One life at a time. For safety information of Imatinib Mesylate Tablets please refer to U.S. Full Prescribing Information at www.ImatinibZeroCopay.comAbout ApotexApotex Inc. is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,500 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. The majority of Apotex sites, including manufacturing, are in North America. Apotex produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex has 500 products under development and will spend $2 billion over the next 10 years on research and development.